Tatalaksana Terkini Infeksi Laten Tuberkulosis pada Anak
DOI:
https://doi.org/10.55175/cdk.v46i2.515Keywords:
Infeksi tuberkulosis, tuberkulosis anakAbstract
Diagnosis infeksi latent tuberkulosis (ILTB) pada anak ditegakkan dari riwayat kontak erat dengan penderita TB aktif serta hasil positif pemeriksaan tuberkulin tanpa manifestasi klinis dan gambaran radiologi TB aktif. Pengobatan ILTB bertujuan untuk mencegah perkembangan menjadi tuberkulosis aktif. Regimen 4 bulan rifampisin setiap hari dan 3 bulan isoniazid-rifapentine setiap minggu lebih direkomendasikan karena memiliki efektivitas dan tingkat keamanan setara tetapi tingkat kepatuhan berobat lebih baik dibandingkan regimen isoniazid setiap hari selama 9 bulan.
The diagnosis of latent tuberculosis infection (LTBI) in children relies on history of exposure and exclusion of clinical symptoms, tuberculin skin test and radiologic findings consistent with active tuberculosis. LTBI treatment is the prevent progression to active tuberculosis. Treatment options recommended include 6-month or 9-month isoniazid, 4-month rifampicin, or 3-month regimen of weekly isoniazid-rifapentine; 4-month daily rifampicin and 3-month regimen of weekly isoniazid-rifapentine were recommended because they had similar rates of safety and efficacy but a better rate of adherence than 9 months of treatment with daily isoniazid.
Downloads
References
World Health Organization. Global tuberculosis report 2017. Geneva: World Health Organization; 2017.
Houben RMGJ, Dodd PJ. The global burden of latent tuberculosis infection: A re-estimation using mathematical modelling. Metcalfe JZ, editor. PLOS Med.2016;13(10):e1002152.
Rieder H. Epidemiologic basis of tuberculosis control. Paris: International Union Against Tuberculosis and Lung Disease; 1999.
World Health Organization. Guidelines on the management of latent tuberculosis infection: the end TB strategy. Geneva: World Health Organization; 2015.
Kementerian Kesehatan RI. Petunjuk teknis manajemen dan tatalaksana TB anak. Jakarta: Kementerian Kesehatan RI; 2016.
Hirsch-Moverman Y, Daftary A, Franks J, Colson PW. Adherence to treatment for latent tuberculosis infection: Systematic review of studies in the US and Canada. Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis. 2008;12(11):1235–54.
Mack U, Migliori GB, Sester M, Rieder HL, Ehlers S, Goletti D, et al. LTBI: Latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur Respir J. 2009;33(5):956–73.
Chegou NN, Heyckendorf J, Walzl G, Lange C, Ruhwald M. Beyond the IFN-γ horizon: biomarkers for immunodiagnosis of infection with Mycobacterium tuberculosis. Eur Respir J. 2014;43(5):1472–86.
Pai M, Denkinger CM, Kik SV, Rangaka MX, Zwerling A, Oxlade O, et al. Gamma interferon release assays for detection of Mycobacterium tuberculosis infection. Clin Microbiol Rev. 2014;27(1):3–20.
Getahun H, Matteelli A, Chaisson RE, Raviglione M. Latent Mycobacterium tuberculosis Infection. Campion EW, editor. N Engl J Med. 2015;372(22):2127–35.
Diallo T, Adjobimey M, Ruslami R, Trajman A, Sow O, Obeng Baah J, et al. Safety and side effects of rifampin versus isoniazid in children. N Engl J Med. 2018;379(5):454–63.
Villarino ME, Scott NA, Weis SE, Weiner M, Conde MB, Jones B, et al. Treatment for preventing tuberculosis in children and adolescents: A randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid. JAMA Pediatr. 2015;169(3):247.
Borisov AS, Bamrah Morris S, Njie GJ, Winston CA, Burton D, Goldberg S, et al. Update of recommendations for use of once-weekly isoniazid-rifapentine regimen to treat latent Mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep. 2018;67(25):723–6.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 https://creativecommons.org/licenses/by-nc/4.0/
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
